Ozge Gumusay1, Guldal Esendagli-Yilmaz2, Aytug Uner3, Bulent Cetin4, Suleyman Buyukberber3, Mustafa Benekli3, Mustafa N Ilhan5, Ugur Coskun3, Ozlem Gulbahar6, Ahmet Ozet3. 1. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Gaziosmanpasa University, 60250, Tokat, Turkey. ozgebostankolu@hotmail.com. 2. Department of Medical Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey. 3. Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey. 4. Department of Internal Medicine, Division of Medical Oncology, Cumhuriyet University Sivas, Sivas, Turkey. 5. Department of Public Health, Faculty of Medicine, Gazi University, Ankara, Turkey. 6. Department of Biochemistry, Faculty of Medicine, Gazi University, Ankara, Turkey.
Abstract
AIM: The aim of the present study was to evaluate the effect of crizotinib on visceral organs in an experimental rat model. METHODS: Eighteen Wistar albino rats were divided into three groups: experimental toxicity was induced with crizotinib (10 mg/kg) administered for 28 days (Group 1), 42 days (Group 2) orally by gavage. Control group received only distilled water. Rats in Group 1 and Group 2 were sacrificed after the collection of blood and tissue samples on the 28th and 42nd days, respectively. RESULTS: Subjects in Group 1 and Group 2 had abnormal histology mainly in lung and liver. There were intraalveolar hemorrhage in lungs; mild portal inflammation, perivenular focal and confluent necrosis in liver; inflammatory reaction in renal pelvis and periureteral areas, and focal pancreatitis in pancreas. CONCLUSION: This study is the first to evaluate the histopathological features of toxicity of crizotinib in a rat model.
AIM: The aim of the present study was to evaluate the effect of crizotinib on visceral organs in an experimental rat model. METHODS: Eighteen Wistar albino rats were divided into three groups: experimental toxicity was induced with crizotinib (10 mg/kg) administered for 28 days (Group 1), 42 days (Group 2) orally by gavage. Control group received only distilled water. Rats in Group 1 and Group 2 were sacrificed after the collection of blood and tissue samples on the 28th and 42nd days, respectively. RESULTS: Subjects in Group 1 and Group 2 had abnormal histology mainly in lung and liver. There were intraalveolar hemorrhage in lungs; mild portal inflammation, perivenular focal and confluent necrosis in liver; inflammatory reaction in renal pelvis and periureteral areas, and focal pancreatitis in pancreas. CONCLUSION: This study is the first to evaluate the histopathological features of toxicity of crizotinib in a rat model.
Authors: Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate Journal: J Clin Oncol Date: 2012-01-03 Impact factor: 44.544
Authors: Evelyn M Brosnan; Andrew J Weickhardt; Xian Lu; Delee A Maxon; Anna E Barón; Michel Chonchol; D Ross Camidge Journal: Cancer Date: 2013-11-20 Impact factor: 6.860
Authors: Yohann Loriot; Gabriel Perlemuter; David Malka; Frédérique Penault-Llorca; Frédérique Penault-Lorca; Valérie Boige; Eric Deutsch; Christophe Massard; Jean Pierre Armand; Jean-Charles Soria Journal: Nat Clin Pract Oncol Date: 2008-03-18
Authors: D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw Journal: Lancet Oncol Date: 2012-09-04 Impact factor: 41.316